首页> 外文期刊>ACS medicinal chemistry letters >BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
【24h】

BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536

机译:PLK1激酶/ BRD4溴结构域抑制剂BI-2536的BRD4结构-活性关系。

获取原文
获取原文并翻译 | 示例
       

摘要

A focused library of analogues of the dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 was prepared and then analyzed for BRD4 and PLK1 inhibitory activities. Particularly, replacement of the cyclopentyl group with a 3-bromobenzyl moiety afforded the most potent BRD4 inhibitor of the series (39j) with a K-i = 8.7 nM, which was equipotent against PLK1. The superior affinity of 39j over the parental compound to BRD4 possibly derives from improved interactions with the WPF shelf. Meanwhile, substitution of the pyrimidine NH with an oxygen atom reversed the PLK1/BRD4 selectivity to convert BI-2536 into a BRD4-selective inhibitor, likely owing to the loss of a critical hydrogen bond in PLK1. We believe further fine-tuning will furnish a BRD4 "magic bullet" or an even more potent PLK1/BRD4 dual inhibitor toward the expansion and improved efficacy of the chemotherapy arsenal.
机译:制备了双重PLK1激酶/ BRD4溴结构域抑制剂BI-2536的类似物聚焦库,然后分析了BRD4和PLK1抑制活性。特别地,用3-溴苄基部分取代环戊基基团提供了K-i = 8.7 nM的最有效的BRD4抑制剂系列(39j),它与PLK1等价。 39j相对于母体化合物对BRD4的优越亲和力可能源于与WPF货架相互作用的改善。同时,用氧原子取代嘧啶NH可逆转PLK1 / BRD4选择性,从而将BI-2536转化为BRD4选择性抑制剂,这可能是由于PLK1中的关键氢键丢失所致。我们相信,进一步的微调将为化学武器库的扩展和提高疗效提供BRD4“神奇子弹”或更有效的PLK1 / BRD4双重抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号